All In Biotech

Drug Trial Radar · NCT03715205

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593)

Last checked: Nov 20, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

150

Actual

Start

Jan 31, 2019

Primary completion

Aug 21, 2024

Study completion Aug 21, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has been designed to evaluate the safety of pembrolizumab in participants in India with unresectable or metastatic melanoma and participants with non-small cell lung cancer (NSCLC) who are either untreated (programmed cell death ligand 1 \[PD-L1\] ≥50%) or have experienced disease progression after a platinum-containing systemic therapy (PD-L1 ≥1%).

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Melanoma

Interventions

  • PembrolizumabDrug

    Administered as an intravenous (IV) infusion every 3 weeks (Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With an Adverse Event (AE)Time frame: Up to approximately 66.5 months
  2. Number of Participants With a Serious Adverse Event (SAE)Time frame: Up to approximately 66.5 months
  3. Number of Participants With a Drug-Related AETime frame: Up to approximately 66.5 months
  4. Number of Participants With a Drug-Related SAETime frame: Up to approximately 66.5 months
  5. Number of Participants Who Discontinued Study Drug Due to an AETime frame: Up to approximately 26 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Rajiv Gandhi Cancer Institute and Research Centre ( Site 0003)

    Delhi, India

  • Nizam's Institute of Medical Sciences ( Site 0011)

    Hyderabad, Andhra Pradesh, India

  • Artemis Health Institute ( Site 0007)

    Gurgaon, Haryana, India

  • Tata Memorial Hospital [M] ( Site 0005)

    Mumbai, Maharashtra, India

  • Kokilaben Ben Dhirubhai Ambani Hosp & Med Res Inst. ( Site 0001)

    Mumbai, Maharashtra, India

  • Deenanath Mangeshkar Hospital and Research Center ( Site 0009)

    Pune, Maharashtra, India

  • All India Institute of Medical Sciences ( Site 0012)

    New Delhi, National Capital Territory of Delhi, India

  • Indraprastha Apollo Hospitals ( Site 0008)

    New Delhi, National Capital Territory of Delhi, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.